After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.Kentucky-based Aristides Capital fully exited its position in the iShares Biotechnology ETF (IBB 0.70%), reducing its portfolio by approximately $3.60 million, according to a November 13 SEC filing.What HappenedAccording to a filing with the Securities and Exchange Commission on November 13, Aristides Capital sold all 28,467 shares of the iShares Biotechnology ETF (IBB 0.70%) previou ...